Topic: priority review voucher
Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GlaxoSmithKline's Zejula for the patient group.
The nod comes as Celgene and Roche are looking to add new indications to their old cancer stalwarts.
Look out, Roche and Regeneron. Thanks to an FDA priority review, Novartis eye candidate brolucizumab could start stealing sales in October.
Analysts believe Novo's oral semaglutide will pull in blockbuster sales, and the company is using a priority review voucher to get to market faster.
Novo Nordisk’s oral semaglutide is heading toward a market shake-up. And the company wants to see that happen sooner rather than later.
Rare disease biotech Ultragenyx has its first FDA nod in Mepsevii, an enzyme therapy expected to carry a high price to treat a tiny group of patients.